The article highlights that Baxter's Q3 earnings will benefit from strong demand and positive pricing, which are typically positive indicators for revenue growth. Additionally, new product launches can drive sales. However, the mention of supply-chain issues suggests potential cost increases, which could offset some of the earnings gains. Overall, the positive factors seem to outweigh the negatives, suggesting a likely positive impact on the stock price.